Tag: CX 2026
Nectero EAST system demonstrates “profound” impact on reducing AAA growth at...
Nectero Therapeutics recently released two-year outcomes data from the company’s first-in-human (FIH) trial of their investigational Nectero Endovascular Aneurysm Stabilisation Treatment (EAST) system. The...
Do women with small AAA need early EVAR? WARRIORS trial investigates
“Women with aortic aneurysms are more likely to die than men with aortic aneurysms.” This was the salient opening line of Colin Bicknell’s (Imperial...
Abbott unveils “promising” Esprit BTK post-approval study data
Initial data from the Esprit BTK post-approval study, presented at the 2026 Charing Cross (CX) Symposium (21–23 April, London, UK), revealed "promising" 30-day results,...
Three-year data highlight durability and differentiated performance of Efemoral vascular scaffold...
Efemoral Medical has announced that Andrew Holden (Auckland City Hospital, Auckland, New Zealand), EFEMORAL I principal investigator, presented three-year results of the first 40...
Leading vascular access surgeons call for solutions to fibrin sheath formation...
Central venous catheters (CVCs) are a widely used form of dialysis access, yet for years the clinical community has avoided discussing how to improve...
Innovation is dead in vascular access? A CX 2026 debate with...
Innovation is dead in vascular access. That was the unenviable challenge Nicholas Inston (Birmingham, UK) took on at the 2026 Charing Cross (CX) Symposium...
IN.PACT AV access post-approval study: Outcomes from extended cohort “consistent with...
Extended cohort outcomes from the IN.PACT arteriovenous (AV) access postmarket study were “clinically reasonable and consistent with prior experience”, the 2026 Charing Cross (CX)...
“Incredible results”: C-GUARDIANS II data point to safety and efficacy of...
New findings from the C-GUARDIANS II study indicate that the CGuard Prime carotid stent system (InspireMD) achieves high procedural success, durable early luminal restoration,...
CX 2026: Carotid trial debate highlights “key question” of cost-effectiveness
An audience poll asking, ‘What do we believe: ECST-2 or CREST- 2?’ following a debate at the 2026 Charing Cross (CX) Symposium (21–23 April,...
Juxtarenal AAA: Global experts drill into PMEG approaches in complex cases...
The use of physician-modified endografts (PMEGs) in juxtarenal abdominal aortic aneurysms (AAAs) through the prism of low-profile endografts, an artificial intelligence (AI)-assisted standardised approach...
CX 2026: Venous and lymphatic session highlights continued innovation following recent PE trials
“Are we at the end of the road with this technology?” asked attendees of yesterday’s opening venous and lymphatic session at the 2026 Charing...
“Absence of endorsement is not absence of evidence”: CX 2026 peripheral...
Debate over sirolimus versus paclitaxel drug-coated balloons (DCBs) in the femoropopliteal segment is shifting from adoption toward optimal use, as new data and expert...
Fully percutaneous bypass a “promising endovascular alternative” for complicated, complex femoropopliteal...
In a podium-first presentation at the 2026 Charing Cross (CX) Symposium (21–23 April, London, UK), Dainis Krievins (Riga, Latvia) shared five-year results from one of...
MOTIV primary efficacy endpoint found to be “clearly superior at 12...
Tim Wittig (Leipzig, Germany) has shared primary outcomes from MOTIV-BTK as a podium-first presentation at the 2026 Charing Cross (CX) Symposium (21–23 April, London, UK)....
One-year aXess data unlock “new category of vascular access”
“Twelve-month results of the aXess show that the graft is safe to implant, supports early and effective dialysis use, and is associated with...
New data in PE care take centre stage in CX 2026...
Newly released HI-PEITHO trial data are among the highlights of this year’s venous programming at the 2026 Charing Cross (CX) Symposium (CX 2026; 21–23...
Innovation meets evidence in CX 2026 vascular access session
What are the best approaches for managing arteriovenous fistula (AVF) stenosis? What role should surveillance play in vascular access management? Is innovation in the...
CX 2026: Global vascular community gathers in London for consensus update
The 48th Charing Cross (CX) Symposium (CX 2026; 21–23 April, London, UK) today opens its doors to vascular and endovascular specialists from around the...
Emerging techniques, PMEGs and robotic surgery: CX 2026 aortic programme features...
Gustavo Oderich (Houston, USA) previews an action-packed three days of aortic programming at this year's Charing Cross (CX) Symposium (CX 2026; 21–23 April, London,...
‘The journey is far from over’: Data updates and subgroup analyses...
“The peripheral arterial programme at will play host to 34 podium-first presentations, including expert and audience analysis, and discussion of landmark trials that...
